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Abstract
Background: Ongoing studies are currently investigating the extent of surgical re-
section required for subsolid cancers. This study aimed to investigate the predictive
factors related to recurrence in patients with clinical stage IA subsolid cancer who
underwent either lobectomy or sublobar resection.
Methods: This was a prospective multicenter observational study conducted in eight
qualifying university teaching hospitals between April 2014 and December 2016. A total
of 173 patients with subsolid nodules pathologically confirmed to have primary lung ade-
nocarcinoma and stage IA disease were included in the final analysis. All patients under-
went lobectomy, segmentectomy, or wedge resection performed by experienced
thoracoscopic surgeons at each site. The surgical procedure was chosen based on the deci-
sion of the surgeons involved. The primary endpoint was time to recurrence (TTR).
Results: The study population was 43.9% (76 of 173) male with a mean age of
60.7 years. During the median follow-up period of 5.01 years, nine patients (5%) expe-
rienced disease recurrence. In the multivariable analysis, tumor size (size ≥2 cm) (haz-
ard ratio: 73.717, 95% confidence interval [CI]: 3.635–895.036; p < 0.001) and stage
IA3 (hazard ratio: 62.010, 95% CI: 2.837–855.185; p < 0.001) were independent pre-
dictors of tumor recurrence. When analyzing the recurrence outcome in patients
according to surgical procedure, no significant difference was found in TTR among
the three groups (i.e., lobectomy, segmentectomy, and wedge resection; p = 0.99).
Conclusions: Patients with radiologically subsolid lung adenocarcinoma measuring
<3 cm could be candidates for sublobar resection instead of lobectomy.
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INTRODUCTION
Computed tomography (CT) is being increasingly used for
lung cancer screening, and findings of incidentally detected
subsolid nodules (either pure ground-glass nodule [GGN]
or part-solid nodule [PSN]) are increasing.1–3 Patients with
stage IA adenocarcinoma observed as subsolid nodules have
been reported to have a better prognosis as compared with
those that are pure solid adenocarcinoma.4,5
Lobectomy demonstrates a great advantage over sublobar
resection and has been naturally recommended as the standard
surgical procedure for early-stage non-small cell lung cancer
(NSCLC).6 However, there is renewed interest in conducting
sublobar resection in selected cases with early-stage NSCLC.
Several studies have shown that sublobar resection achieves
equivalent surgical outcomes to those of lobectomy in clinical
stage IA subsolid lung cancer.7–9 Previous guidelines from the
Fleischner Society recommend the management of persistent
subsolid nodules; however, the optimal extent of surgical re-
section and mediastinal lymph node dissection has yet to be
determined.10, 11 This study aimed to investigate predictive fac-
tors related to the recurrence in patients with clinical stage IA




This study was a prospective multicenter observational study
conducted in eight qualifying university teaching hospitals.
Between April 2014 and December 2016, 250 patients with
subsolid nodules indicated for surgical resection under
video-assisted thoracoscopic surgery (VATS) were screened
and enrolled from the eight sites according to the inclusion
criteria. Of the 250 patients from the LOGIS trial,12 we pro-
spectively enrolled all eligible patients according to the
inclusion criteria of the present study as follows: (i) aged
more than 20 years, (ii) pulmonary lesion with a GGN com-
ponent of greater than 50%, (ii) a lesion size of less than
3 cm, (iv) clinical stage IA disease (according to the TNM
classification scheme, eighth edition), and (v) pathologically
confirmed as having primary lung adenocarcinoma or ade-
nocarcinoma in situ (AIS). The exclusion criteria were as
follows: (i) an unwillingness or inability to provide consent,
(ii) disease pathologically confirmed as benign or something
other than primary lung adenocarcinoma, (iii) patients with
synchronous subsolid or pure solid tumors, (iv) patients
who were classified as not having stage IA disease, and
(v) follow-up loss. The study protocol was approved by the
institutional review boards or ethics committees at each par-
ticipating center and all participants provided their written
informed consent.
Finally, 173 patients with subsolid nodules pathologi-
cally confirmed to have primary lung adenocarcinoma and
pathological stage IA disease (according to the TNM classifi-
cation scheme, eighth edition), were included for final analy-
sis (Figure 1). All patients underwent thoracoscopic surgery
conducted by experienced thoracoscopic surgeons at each
site. All data entry, data management, and analyses were
coordinated or performed at a data-coordinating center. In
our database, the following clinical and pathological charac-
teristics were recorded: age, sex, clinical history including
hypertension, diabetes mellitus, hepatitis, cancer (other than
lung cancer), surgery (other than lung cancer surgery), heart
disease, and smoking, maximum tumor size including GGN
component, solid size, stage based on the eighth edition of
the TNM classification scheme, surgical method, and patho-
logical type including histological subtype.
Chest CT examinations
All preoperative chest CT examinations were performed
using a (at minimum) 16-slice multi-detector single- or
dual-source CT scanner. A chest CT was performed in all
eligible participants in a craniocaudal direction during inspi-
ration without contrast material enhancement by using the
following scan parameters: tube voltage, 120 kV; tube cur-
rent, 100 mAs, section thickness and interval, 1.0 and
1.0 mm, respectively.
Image and pathology analysis
All image analyses were performed at the data-coordinating
center by an experienced board-certificated thoracic radiolo-
gist with 10 years of experience in chest CT imaging who
was blinded to the clinical and histological findings. TNM
staging was based on the eighth edition of the TNM classifi-
cation proposed by the International Association of Study of
Lung Cancer (IASLC).13
Subsolid nodules were distinguished depending on the
presence of GGN and solid components. Pure GGN was
defined as a nodule without a solid component and a PSN
was defined as a lung lesion with both a GGN and a solid
component.11 The maximum diameter on the single larg-
est dimension (axial, sagittal, or coronal images) was measuredF I G U R E 1 Flow chart of patient selection
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on a lung window and recorded for determining the size of the
solid component and whole target nodule. For quantitative vol-
ume analysis, commercialized software (AVIEW Research) was
used to measure the whole tumor volume. The lesion segmen-
tation was performed on a lung window setting (width, 1500
HU; level, −600 HU) images. The whole volume of interest
(VOI) of the target lesion was isolated by semi-automatic seg-
mentation. If the segmented border of the target lesion was
incorrect, the reviewer manually corrected the VOI according
to the border of the target lesion on slices including the target
lesion on axial images. When the observer approved the defini-
tion of the margin, the program automatically calculated the
tumor volume.
The postoperative pathological diagnosis was made
according to the IASLC/American Thoracic Society/European
Respiratory Society classification as adenocarcinoma in situ,
minimally invasive adenocarcinoma, or invasive
adenocarcinoma which was further divided into lepidic pre-
dominant, acinar predominant, papillary predominant, micro-
papillary predominant, solid predominant, and invasive
mucinous adenocarcinoma. The predominant pattern was
defined as the pattern with the largest percentage (not neces-
sarily 50% or higher).14
Follow-up protocol
All patients were followed up from the day of surgery. They
were examined physically and underwent chest CT covering
cervical to abdominal lesions every 3–6 months for the first
two years. Thereafter, they were examined physically and by
chest CT every six months during the third year and then
once per year for subsequent years up to five years. The pri-
mary endpoint of the present study was time to recurrence
T A B L E 1 Baseline characteristics of 173 patients with pathological stage IA primary lung adenocarcinoma
Variables Lobectomy (n = 63) Segmentectomy (n = 41) Wedge resection (n = 69) p-value
Sex (male %) 23 (36.5) 19 (46.3) 34 (49.2) 0.191
Age (years) 59.84  8.72 61.12  10.68 61.37  11.49 0.534
Hypertension, n (%) 21 (33.3) 17 (41.5) 20 (28.9) 0.627
Diabetes, n (%) 10 (15.8) 9 (21.9) 9 (13.0) 0.590
Hepatitis, n (%) 3 (4.7) 3 (7.3) 5 (7.2) 0.597
Canceraa, n (%) 12 (19.0) 15 (36.6) 26 (37.6) 0.039
Surgerybb, n (%) 29 (46.1) 28 (68.3) 42 (60.8) 0.139
Heart disease, n (%) 4 (6.3) 9 (21.9) 5 (7.2) 0.962
Smoking status 0.222
Current/former, n (%) 16 (25.4) 16 (39.0) 32 (46.4)
Never, n (%) 47 (74.6) 25 (61.0) 37 (53.6)
Tumor size, mm 16.88  5.07 15.64  3.47 14.44  5.15 0.019
Solid component, mm 7.24  4.94 4.60  3.24 4.19  3.87 <0.001
Whole tumor volume, mm3 2408.66  2319.01 1805.94  1372.85 1687.53  2018.48 0.025
Pure GGN 9 (14.3) 11 (26.8) 23 (33.3) 0.029
Part solid nodule 54 (85.7) 30 (73.2) 46 (66.7) 0.025
Location, n (%) 0.007
Right upper lobe 21 (33.3) 8 (19.5) 23 (33.3)
Right middle lobe 9 (14.3) 0 5 (7.2)
Right lower lobe 9 (14.3) 6 (14.6) 19 (27.5)
Left upper lobe 17 (26.9) 21 (51.3) 15 (21.9)
Left lower lobe 7 (11.2) 6 (14.6) 7 (10.1)
p-stage 0.066
Stage IA1 12 (19.0) 7 (17.1) 23 (33.3)
Stage IA2 40 (63.5) 32 (78.0) 41 (59.5)
Stage IA3 11 (17.5) 2 (4.9) 5 (7.2)
Histology type 0.259
MIA 12(19.0) 10(24.4) 21 (30.4)
Invasive adenocarcinoma 51(81.0) 31(75.6) 48 (69.6)
Note: Values are presented as mean  standard deviation or patient number with (%).
Abbreviations: GGN, ground-glass opacity; MIA, minimally invasive adenocarcinoma.
aHistory of cancer included all cancers other than lung cancer.
bHistory of surgery included surgery other than lung cancer surgery.
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(TTR), which was defined as the time from the day of sur-
gery to the day of first recurrence. Local recurrence was
defined as disease recurrence at the surgical re-
section margin, ipsilateral hilum, and/or mediastinum. All
other sites of failure were considered distant recurrences.
Patients who died from other causes during the study period
were considered to be censored with no event when calculat-
ing TTR. Observations were censored at the last follow-up
at which the patient was alive or lost to follow-up.
Statistical analysis
The differences between categorical variables were ana-
lyzed by chi-squared test. Differences between continuous
variables were analyzed by the one way ANOVA test or
Kruskal-Wallis test. A Cox proportional-hazards regres-
sion model was used to evaluate the risk factors for lung
cancer-related recurrence among the different surgical
methods. Statistically significant findings on univariate
analysis were subsequently included in the multivariate
analysis. Only variables with p-values of less than 0.20
during univariate analysis were added to the final multi-
variate models to prevent model overfitting. From the
Cox proportional-hazards model, hazard ratios (HRs) and
95% confidence intervals (CIs) were calculated with using
Firth correction. Concordance (C) statistics were used to
compare the predictive prognosis among the models.15
Survival curves were estimated by the Kaplan–Meier
method according to the three different surgical groups.
T A B L E 2 Univariate analysis using a Cox proportional-hazards regression model
Time-to recurrence
Characteristic HR 95% CI p value
Age 1.056 0.982 1.135 0.143
Sex (male) 0.623 0.157 2.475 0.503
Hypertension 1.689 0.351 8.134 0.513
Diabetes 1.406 0.176 11.249 0.748
Hepatitis 1.093 0.049 24.501 0.952
Cancer 1.643 0.341 7.912 0.536
Surgery 5.897 0.739 47.230 0.095
Heart disease 0.890 0.022 8.871 0.523
Smokinga 1.501 0.402 5.601 0.546
Tumor size, cm
Size < 2 cm 1 (ref )
Size ≥ 2 cm 63.404 3.161 971.714 <0.001
Subsolid nodule subtype
Pure GGN 1 (ref)
Part-solid nodule 2.093 0.259 16.938 0.489
Solid size, mm
Size < 6 mm 1 (ref)
Size ≥ 6 mm 2.245 0.559 9.012 0.254
Tumor volume (*100), mm3
Volume < 10 1 (ref)
Volume ≥ 10 11.012 0.559 220.872 0.017
Surgery
Lobectomy 1 (ref)
Segmentectomy 0.839 0.153 4.613 0.840
Wedge resection 0.864 0.190 3.935 0.851
Stage
Stage IA1 1 (ref)
Stage IA2 0.867 0.005 25.373 0.623
Stage IA3 47.787 2.211 832.707 <0.001
Histology type
MIA 1 (ref)
Invasive adenocarcinoma 2.723 0.341 21.776 0.345
Abbreviations: AIS, adenocarcinoma in situ; CI, confidence interval; GGN, ground-glass opacity; HR, hazard ratio; MIA, minimally invasive adenocarcinoma.
asmoking included all former and current smokers.
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Their comparisons were performed by using the log-rank
test. Here, p-values of less than 0.05 were considered sta-
tistically significant. All statistical analyses were
performed using commercial software (R version 3.3.2
from the R Foundation for Statistical Computing and
MedCalc version 12 from MedCalc).
T A B L E 3 Multivariate analysis using a Cox proportional-hazards regression model
Time-to recurrence
Model 1 HR 95% CI p value
Surgery
Lobectomy 1 (ref)
Segmentectomy 0.839 0.153 4.613 0.840
Wedge resection 0.864 0.190 3.935 0.851
Time-to recurrence
Model 2 HR 95% CI p-value
Surgery
Lobectomy 1 (ref)
Segmentectomy 2.368 0.443 12.664 0.304
Wedge resection 1.241 0.27 5.704 0.765
Tumor size, cm
Size < 2 cm 1 (ref)
Size ≥ 2 cm 73.717 3.635 895.036 <0.001
Time-to recurrence
Model 3 HR 95% CI p-value
Surgery
Lobectomy 1 (ref)
Segmentectomy 0.935 0.174 5.017 0.932
Wedge resection 1.176 0.258 5.373 0.822
Tumor volume (*100), mm3
Volume < 10 1 (ref)
Volume ≥ 10 11.447 0.559 234.245 0.016
Time-to recurrence
Model 4 HR 95% CI p-value
Surgery
Lobectomy 1 (ref)
Segmentectomy 1.06 0.188 5.982 0.948
Wedge resection 1.146 0.239 5.494 0.864
Solid size, mm
Size < 6 mm 1 (ref)
Size ≥ 6 mm 2.319 0.547 9.84 0.254
Time-to recurrence
Model 5 HR 95% CI p-value
Surgery
Lobectomy 1 (ref)
Segmentectomy 3.882 0.641 23.519 0.141
Wedge resection 1.258 0.27 5.867 0.751
Stage
Stage IA1 1 (ref)
Stage IA2 0.841 0.005 22.722 0.599
Stage IA3 62.01 2.837 855.185 <0.001
Abbreviations: CI, confidence interval; HR, hazard ratio.
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RESULTS
Patient characteristics
Overall, the study population consisted of 173 patients
with clinicopathological stage IA primary lung adenocar-
cinoma; among these, 43.9% (76 of 173) were male with a
mean age of 60.7 years. The clinical characteristics of the
patient population according to surgical procedures are
listed in Table 1. In the lobectomy group, history of can-
cer was significantly lower compared to segmentectomy
and wedge resection groups (p = 0.039). The tumor size,
solid component and volume were higher in the lobec-
tomy group than segmentectomy and wedge re-
section groups (all p < 0.001). The lobectomy group had
higher part-solid nodules than segmentectomy and wedge
resection groups (p < 0.001), whereas the wedge re-
section group had higher pure GGN than segmentectomy
and lobectomy groups (p < 0.001).
Recurrence outcome
During the median follow-up period of 5.01 years (inter-
quartile range: 4.33–5.45 year), nine patients experienced
disease recurrence: ipsilateral or contralateral lung (n = 6),
brain (n = 2), and LN (mediastinum) (n = 1). Disease recur-
rence was confirmed by means of biopsy or surgery in four
(44%) patients, while the remaining five (56%) patients were
confirmed by means of CT, MRI or PET scan.
When patients were divided into lobectomy,
segmentectomy, and wedge resection subgroups, three
patients with disease recurrence underwent wedge resection,
two underwent segmentectomy, and four underwent lobec-
tomy. The pathological TNM stage of the nine patients with
disease recurrence was stage IA3. All patients were con-
firmed to have invasive adenocarcinoma (five with papillary
predominant and four with acinar predominant).
In a univariate Cox regression analysis, tumor size (size
≥ 2 cm) (HR: 63.404, 95% CI: 3.161–971.714; p < 0.001),
T A B L E 4 C-statistics for the prediction of disease recurrence
C-statistics for model with disease recurrence
Model C-index Difference (95% CI) Model comparison p-value
Model 1: Surgery 0.516 NA NA
Model 2: Surgery + tumor size 0.718 0.202 (−0.015, 0.419) 0.041
Model 3: Surgery + tumor volume 0.565 0.049 (−0.018, 0.117) 0.754
Model 4: Surgery + solid size 0.523 0.007 (−0.075, 0.089) 0.871
Model 5: Surgery + stage 0.740 0.224 (−0.079, 0.527) 0.032
Note: Model comparison between Model 1 vs. Model 2, Model 1 vs. Model 3, Model 1 vs. Model 4 and Model 1 vs. Model 5.
F I G U R E 2 Time to recurrence in
patients with adenocarcinoma presented as
subsolid nodule stratified according to
surgical procedure
946 IM ET AL.
tumor volume (volume ≥ 10[*100] mm3) (HR: 11.012, 95%
CI: 0.559–220.872; p = 0.017) and stage IA3 (HR: 47.787,
95% CI: 2.211–832.707; p < 0.001) were deemed predictors
of disease recurrence (Table 2). To determine the prognostic
predictors between surgical procedures, we constructed sev-
eral models with additional parameters. All variables met a
proportional-hazards assumption. In models 2 and 5, tumor
size (size ≥ 2 cm) (HR: 73.717, 95% CI: 3.635–895.036;
p < 0.001) and stage of IA3 (HR: 62.01, 95% CI:
2.837–855.185; p < 0.001) were independent predictors of
tumor recurrence (Table 3).
The incremental benefit of additional parameters was
assessed using C-statistics as shown in Table 4. With regard
to disease recurrence, the benefits of tumor size (model 2)
and stage (model 5) were significant as compared with the
surgical procedure (model 1) (C-index: 0.718 vs. 0.516, and
0.740 vs. 0.516, respectively; all p < 0.05).
When analyzing the recurrence outcomes among
patients according to surgical procedures, the log-rank test
revealed no significant difference in RFS among the three
groups (i.e., lobectomy, segmentectomy, and wedge resec-
tion; p = 0.99) (Figure 2).
DISCUSSION
In this study, we found that radiologically subsolid lung can-
cer in patients measuring less than 3 cm had an excellent
surgical outcome regardless of surgical procedures, subsolid
nodule subtype and solid component size. In addition, the
TTR was not significantly different among the various surgi-
cal procedures (i.e., whether the patients underwent lobec-
tomy, segmentectomy, or wedge resection). The findings in
this study may help to guide surgical procedure selection in
patients with clinical stage IA adenocarcinoma observed as
subsolid nodules.
On the basis of the current evidence, the standard surgi-
cal treatment for primary lung cancer is still lobectomy, even
though several trials to date have explored the use of sub-
lobar resection for lung cancer.7–9, 16–18 One previous study
using a national cancer database in the United States dem-
onstrated that patients who underwent sublobar resection for
stage IA NSCLC had poorer oncological outcomes.19 On the
other hand, a previous meta-analysis demonstrated that
patients with tumors measuring less than 2 cm located
peripherally with favorable histopathology and with GGN
on CT imaging might be candidates for sublobar re-
section instead of lobectomy.20 Our study results were con-
sistent with these findings. In our study, there was no
recurrence among patients with tumors that were smaller
than 2 cm regardless of surgical procedures, subsolid nodule
subtype and solid component size. We found that tumor size
larger than 2 cm and stage IA3 were independent risk fac-
tors of disease recurrence in patients with clinical stage IA
subsolid adenocarcinoma.
Regarding part-solid tumors, several studies have previ-
ously demonstrated that solid component size correlates
more accurately with tumor invasiveness and prognosis than
maximum tumor size.4,21,22 Currently, the size of the solid
component is applied to the category T stage for part-solid
lung cancers according to the eighth edition of the TNM
classification scheme of lung cancer because the solid com-
ponent is regarded as the invasive component.23 However,
our study showed that solid component size was not an
independent predictor of tumor recurrence. Our results
appear to be inconsistent with the results of several previous
studies.4,21,22 The reason why our results were different from
previous studies may be related to our exclusion of pure
solid tumor when considering the effect of solid component
size. Although the solid component in a PSN by CT has a
greater chance of having an invasive component on histo-
logical examination, the solid area could also represent a
benign scar or a fibrous scar.24 In addition, managing PSNs
with several solid components can be a challenge because
there is currently no consensus regarding how the solid
components of these lesions should be measured.
There is still no strong evidence based on a randomized
controlled trial for the extent of surgical resection for sub-
solid nodules. However, the results of this study validate and
support the NCCN guideline (version 5, 2020) recommen-
dation to guide surgical procedure selection in patients with
clinical stage IA adenocarcinoma observed as subsolid
nodules.
We acknowledge that there are some limitations and
biases in our study. First, this study did not proceed with a
randomized controlled investigation. For surgical methods,
patients were not evenly assigned to lobectomy,
segmentectomy, or wedge resection. In addition, the nodal
sampling was not uniformly performed in each center. In
the lobectomy and segmentectomy groups, all patients
underwent mediastinal lymph node dissection. However, in
the wedge resection group, 24 (34.2%) patients did not
undergo mediastinal lymph node dissection. Second, the
recurrence rate was very small. Only nine patients experi-
enced disease recurrence. Therefore, depending on the
recurrence rate, these results may be affected. To reduce the
bias from low recurrence rate, we applied Firth correction
when calculating 95% CI. Third, there was not enough
follow-up time after surgery to evaluate overall survival. The
median follow-up period was 5.01 years (interquartile range:
4.33–5.45 years). In this study, we evaluated the TTR instead
of overall survival because in stage I disease more patients
died from causes other than from cancer during the follow-
up period.
In conclusion, radiologically subsolid lung adenocarci-
noma measuring <3 cm could be candidates for sublobar
resection instead of lobectomy. In our study, subsolid lung
cancer measuring smaller than 3 cm had excellent surgical
outcome regardless of surgical procedures, subsolid nod-
ule subtype and solid component size. In addition, the
TTR was not significantly different among the various
surgical procedures of lobectomy, segmentectomy, or
wedge resection in patients with clinical stage IA adeno-
carcinoma observed as subsolid nodules. While these
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results need to be replicated in larger randomized con-
trolled studies, our results validate subjects eligible for
sublobar resection recommended by NCCN 2020 guide-
line and provide the surgeon with a rationale for choosing
a less-extensive surgical alternative for clinical stage IA
adenocarcinomas observed as subsolid nodules without
compromising patient outcomes.
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